r adverse reactions/interactions ALTERED IMMUNE RESPONSES ASSOCIATED WITH PRACTOLOL ... Are They Of Primary Importance In The Oculomucocutaneous Syndrome? A primary immunological mechanism has been suggested for the oculomucocutaneous syndrome in patients on practolol. Accordingly, 18 patients with different symptoms of the syndrome were compared with 14 practolol-treated patients without adverse effects and 35 controls who had never taken practolol. Patients on practolol (200-2400mg/day) with and without adverse reactions showed altered immune responses. At the time of the study some patients had been offpractolol for up to 36 months, but still showed symptoms. There was no response to skin tests with Candida albicans and streptokinase/ streptodornase in most patients with practolol symptoms, whereas those on practolol for only 3-6 months and controls gave positive responses to both. The overall lymphocyte response was lowered in patients with symptoms and in those without symptoms who had been on practolol for 2 years. All immunoglobulin concentrations were normal, but autoantibodies were detected in most patients on practolol with or without symptoms (even in 3 of 5 on practolol for up to 6 months only). Antinuclear antibody and rheumatoid factor were common in those with the oculomucocutaneous syndrome. There was some anticomplementary activity in treated patients, but serum DNA- binding was normal in all. 'Thus, although several anomalies can be detected in the immunological status of patients in whom the oculomucocutaneous syndrome developed in response to practolol, it is not possible to demonstrate that they are of primary importance in the genesis of the condition.' Behan, P.O. et ai.: Lancet 2: 984 (6 Nov i 976) INPHARMA 13th November, 1976 p4

ALTERED IMMUNE RESPONSES ASSOCIATED WITH PRACTOLOL

Download PDF Report

Upload
buidan
View
215
Download
1

Embed Size (px)

Citation preview

adverse reactions/interactions

ALTERED IMMUNE RESPONSES ASSOCIATED WITH PRACTOLOL

... Are They Of Primary Importance In The Oculomucocutaneous Syndrome? A primary immunological mechanism has been suggested for the oculomucocutaneous syndrome in patients on practolol. Accordingly, 18 patients with different symptoms of the syndrome were compared with 14 practolol-treated patients without adverse effects and 35 controls who had never taken practolol. Patients on practolol (200-2400mg/day) with and without adverse reactions showed altered immune responses. At the time of the study some patients had been offpractolol for up to 36 months, but still showed symptoms.

There was no response to skin tests with Candida albicans and streptokinase/ streptodornase in most patients with practolol symptoms, whereas those on practolol for only 3-6 months and controls gave positive responses to both. The overall lymphocyte response was lowered in patients with symptoms and in those without symptoms who had been on practolol for 2 years. All immunoglobulin concentrations were normal, but autoantibodies were detected in most patients on practolol with or without symptoms (even in 3 of 5 on practolol for up to 6 months only). Antinuclear antibody and rheumatoid factor were common in those with the oculomucocutaneous syndrome. There was some anticomplementary activity in treated patients, but serum DNAbinding was normal in all.

'Thus, although several anomalies can be detected in the immunological status of patients in whom the oculomucocutaneous syndrome developed in response to practolol, it is not possible to demonstrate that they are of primary importance in the genesis of the condition.'

Behan, P.O. et ai.: Lancet 2: 984 (6 Nov i 976)

INPHARMA 13th November, 1976 p4